MiNK Therapeutics, Inc. (INKT)
MiNK Therapeutics develops iNKT cell therapy candidates for cancers and graft versus host disease, still in clinical trials. It last closed at $9.29 on Nov 17, down 0.16% on the day. The average 12-month price target from 2 analysts is $44.00 (+373.9% from the last close), with a high of $50.00 and a low of $38.00.
Key Stats
Last 12 monthsNot reported for this period.
From INKT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 2 analysts who set a price target on INKT in the past 90 days. The average target is $44.00, with a high of $50.00 and a low of $38.00, compared with the last close of $9.29.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 4 | HC Wainwright & Co. | Assumed coverage | Buy | $38 |
| Oct 21 | B. Riley Securities | Reiterated | Buy | $50 |
Technical Analysis
The stock is 10% below its 20 day and 18% below its 50 day average. It is 20% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot at $9.27, and the nearest resistance the Pivot R1 at $9.32.
| RSI (14) | 37.75 | Weak, oversold below 30 | Neutral |
| MACD | -0.41 | Below its signal line | Bearish |
| Stochastic | 9.2 | Near the bottom of its range | Oversold |
| ADX (14) | 17.7 | No clear trend | |
| Williams %R | -87.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -161.6 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −13.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.69 | Typical daily range, 7.5% of price |
| RSI (14) | 40.44 | Middle of its range | Neutral |
| MACD | -0.48 | Below its signal line | Bearish |
| Stochastic | 11.7 | Near the bottom of its range | Oversold |
| ADX (14) | 27.5 | Trending down | |
| Williams %R | -92.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -175.4 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −22.6% | Change over 10 sessions | Bearish |
| ATR (14) | $1.55 | Typical daily range, 16.7% of price |
What happened before
See how INKT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How INKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in INKT in the last 90 days.
INKT Institutional Ownership
Full report →- ▼6 buying vs 10 selling
- ●Held by funds -0.5 pts
- ▼Funds holding -3
- ▼Superinvestors: 0 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 26 | 29 | −10.3% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 3.8% | 4.2% | −0.5 pts |
| New / increased | 1 / 5 | 8 / 6 | −57.1% |
| Reduced / sold out | 6 / 4 | 3 / 3 | +66.7% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INKT is in one of them and how their past INKT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered INKT in an article yet. Here's the latest on the wider market.
About MiNK Therapeutics
MiNK Therapeutics is a biotechnology company based in New York that develops cell therapies built on its iNKT cell platform. Its product candidates are still being tested in clinical trials and have not been approved for sale. The treatments are being studied for conditions such as graft versus host disease, solid tumors and multiple myeloma, and the company's intended customers are patients and the physicians who treat them. It competes with other cell therapy developers and with existing and newer treatments.
- Headquarters
- New York, NY
